Agilent Technologies, Inc. - 10-K Filing Summary
Business Context and Reporting Period
This filing covers the fiscal year ended October 31, 2025. Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied markets. In November 2024, the company reorganized its operations into three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Historical data has been recast to reflect this new structure. The company employs approximately 18,100 people worldwide.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Net Revenue | $6,948 million | $6,510 million | +7% |
| Net Income | $1,303 million | $1,289 million | +1% |
| Diluted EPS | $4.57 | $4.43 | +3% |
| Operating Margin | 21.3% | 22.9% | -1.6 ppts |
| Gross Margin | 52.4% | 54.3% | -1.9 ppts |
| Operating Cash Flow | $1,559 million | $1,751 million | -11% |
| Cash & Equivalents | $1,789 million | $1,329 million | +34% |
| Total Debt | $3.4 billion | $3.4 billion | Flat |
Note: Total debt includes $3.3 billion in unsecured senior notes and short-term borrowings.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 7% year-over-year, driven by growth across all segments and geographic regions. The Life Sciences and Diagnostics Markets segment led with 11% growth, significantly aided by the BIOVECTRA acquisition (contributing ~5 percentage points to segment growth). Agilent CrossLab grew 6%, while Applied Markets grew 1%.
- Margin Compression: Total gross margin decreased by 1.9 percentage points and operating margin by 1.6 percentage points. Management attributed this to higher tariffs and shipping costs, unfavorable business mix (specifically lower margins in the specialty CDMO business), higher wages, and restructuring expenses.
- Restructuring: The company incurred $82 million in restructuring costs in 2025, primarily related to a new plan (FY25 Plan) to optimize management structure, compared to $76 million in 2024.
- Tax Rate: The effective tax rate dropped significantly to 9.2% in 2025 from 15.3% in 2024. This was driven by a $57 million federal tax benefit from an intra-entity asset transfer, a $29 million benefit from foreign-derived intangible income, and a $28 million release of tax reserves.
Guidance, Outlook, and Risks
- Tariff Impact: Recent tariff changes adversely impacted costs of revenue in the second half of fiscal 2025. Management expects to substantially mitigate this impact in fiscal 2026 through supply chain optimization and targeted pricing actions.
- Capital Expenditures: Anticipated capital expenditures for fiscal 2026 are approximately $500 million, primarily for expanding manufacturing capacity for nucleic acid-based therapeutics in Frederick, Colorado.
- Share Repurchases: The 2023 repurchase program ($2.0 billion authorization) was completed in September 2025. The company commenced the 2024 repurchase program ($2.0 billion authorization) in September 2025, with approximately $1.9 billion remaining as of year-end.
- Dividends: A quarterly dividend of $0.255 per share was declared on November 19, 2025, payable in January 2026.
- Risks: Key risks include geopolitical instability and trade policies (tariffs), supply chain disruptions, customer capital spending constraints (particularly in the pharmaceutical sector), and the impact of new tax legislation (OBBBA and Pillar Two rules) expected to increase income taxes in fiscal 2026.
Investor Verification Checklist
- Tariff Mitigation: Verify the effectiveness of pricing actions and supply chain changes in fiscal 2026 to offset the cost increases seen in late 2025.
- CDMO Margins: Monitor the gross margin trajectory of the specialty CDMO business (BIOVECTRA) to ensure it stabilizes as volume scales.
- Tax Normalization: Assess the sustainability of the 9.2% effective tax rate, noting the one-time benefits and the expected increase in tax liability due to new legislation in 2026.
- Government Funding: Evaluate the impact of U.S. federal government funding reductions on the Academic and Government end markets, which saw revenue declines in 2025.
- Debt Maturity: Review the upcoming maturity of the $300 million 2026 Senior Notes (due September 2026) and the company's refinancing or repayment strategy.